Molecular medicine is beginning to provide hope for patients with declining sight when all other therapies have been exhausted, according to an expert.
These low-cost preventive molecular medicine approaches have worked without fail so far, said physician Richer.
He revealed six separate cases where molecular medicine sometimes improved functional vision within days, which was unexpected.
A recent case is an 88-year old woman with macular degeneration, an age-related eye disorder that robs seniors of their central vision, Richer said.
age-related macular degeneration
Employing a molecular medicine regimen, this hospitalized woman regained her ability to see faces, read a menu and visualize her handwriting in just four days. Her vision improvement was in both eyes, according to him.
“A second 88-year old patient, this time with “dry” macular degeneration, took 10 weeks to see clinical improvement, but by 20 weeks the retina appeared to return to a more youthful appearance with 20/20 vision,” he added.
Richer said typically in the cases he has monitored, blind spots (called scotomas) disappear, time to recover from bright light (glare recovery test) is reduced, and contrast vision (shades of grey) as well as visual acuity (ability to see letters on a chart) generally improve within 3-6 weeks on a molecular medicine regimen that provides small molecules that bind to (chelate) to minerals such as copper, iron and calcium.
Richer selected a nutriceutical mixture of vitamins and small molecules (Longevinex) extracted from herbs and vitamins to produce these rapid improvements in functional vision because of its extensive testing and proven ability to favorably alter genes in a superior manner to other available nutriceuticals.
He said the human eye apparently has untapped regenerative capacity that can be activated with molecules found in nature.
The findings were presented at 4th annual Nutrition and The Eye conference, April 16-17 in St. Louis.
- Similar posts
- Vitamin D and AMD in females (29.5%)
- Age related macular degeneration update (27%)
- Parkinson's disease linked to metal pollution (26.4%)
- Stem cell treatment for Stargardt’s macular dystrophy (22.2%)
- Victoria park - Kitchener - Ontario (20.3%)
A groundbreaking study may offer a cheap drug to people who are losing their sight.
The study showed that the bowel cancer drug Avastin could stop patients with an age-related disease from going blind.
It is as effective as a very similar drug Lucentis, which is made by the same company but is up to 100 times more expensive.
Trial results showed that Avastin works as well as Lucentis.
The results of other trials due in the next few months could force the UK Government to ask National Institute for Health and Clinical Excellence (Nice) to offer guidance on prescribing it.
The Macular Disease Society welcomed the findings but said Lucentis should continue to be prescribed until safety data was available.
“This is encouraging news for those who have no treatment option other than Avastin either because they have other forms of macular disease, or their health care provider does not offer Lucentis,” the Daily Express quoted a spokesman as saying.
The study has been published in the New England Journal of Medicine.